

This press release may not be published, distributed or disseminated, directly or indirectly, in part or in its entirety, to or within the United States, Australia, Canada, Japan or any other country where this would constitute a violation of applicable laws.

Disclosure of stabilization operations performed

Press release

Avignon, 25 November 2011 - CM - CIC Securities, acting in his capacity as manager of the stabilization in the context of the capital increase of NATUREX, declares, pursuant to Article 631-10 of the General Regulations of the AMF (French Market Authorities) that:

- i. it has conducted stabilization operations,
- ii. the first stabilization operation was conducted on October 7, 2011 and the final stabilization operation was conducted on October 13, 2011,
- iii. the stabilization operations were performed at the following prices:

Naturex (FR0000054694)		
	Lower limit	Upper limit
07/10/2011	€ 47.63	€ 48.72
10/10/2011	€ 48.46	€ 48.61
11/10/2011	€ 47.89	€ 47.89
12/10/2011	€ 49.10	€ 49.10
13/10/2011	€ 47.74	€ 49.58

Naturex BSA (FR0011128768)		
	Lower limit	Upper limit
07/10/2011	€ 1.700	€ 2.054
10/10/2011	€ 2.050	€ 2.100
11/10/2011	€ 1.800	€ 1.800
12/10/2011	€ 1.850	€ 1.870
13/10/2011	€ 2.150	€ 4.500

This press release shall not be distributed, published or released in the United States of America (including its territories and possessions, every State in the United States and the District of Columbia), Australia, Canada or Japan.

This press release and the information contained herein do not constitute an offer to sell or to subscribe securities or the solicitation of an offer to buy or subscribe securities in other jurisdictions than France. The release of this press release in certain jurisdictions may be restricted by law. Therefore persons in such jurisdictions into which this press release is released, published or distributed must inform themselves about and observe such restrictions.

This press release does not constitute an offer to sell securities or the solicitation of an offer to buy or subscribe to securities in the United States or any other countries. The securities mentioned in this press release have not been and will not be registered under the United States Securities Act of 1933, as amended and may not be offered or sold in the United States or to a US Citizen or for his behalf absent registration or exemption from registration under the Securities Act. There will not be any public offering of securities in the United States of America.





Naturex has been listed since October 1996 on NYSE Euronext Paris, Compartment B (MidCaps)



Number of shares comprising the capital: 7,705,580

- ▶ 6,318,272 ordinary shares (ISIN FR0000054694)
- ▶ 1,387,308 preferred shares (ISIN FR0000054694)

Naturex is a component of the CAC Small and Gaïa indexes. Naturex is eligible for "long only" Deferred Settlement Service (SRD).

TICKER: NRX - Reuters: NATU.PA - Bloomberg: NRX:FP

About Naturex

NATUREX is the global leader in specialty plant-based natural ingredients.

The Group is organised around three strategic markets (food & beverage, nutrition & health and personal care) and produces and markets specialty plant-based ingredients for the food, nutraceutical, pharmaceutical and cosmetic industries.

NATUREX's head office is based in Avignon. The company employs more than 1,000 people with high-performance manufacturing operations across 13 sites in Europe (France, Italy, Spain, the United Kingdom and Switzerland), as well as in Morocco, the United States, Brazil and Australia. It also has a global presence through a dedicated network of sales offices in 18 countries (France, Italy, Spain, the United Kingdom, Belgium, Germany, Russia, U.A.E., Thailand, Singapore, Japan, China, Korea, Australia, the United States, Canada, Brazil and Mexico).

NATUREX's development is supported by positive underlying trends linked to a fast-growing demand for natural products and its capacity to provide manufacturers customised solutions to meet the requirements of their end consumers. The Group's strength lies in its positioning with specific products which constitute niche markets, supported by strong sourcing capacity and sustained research & development.

Contacts

Jacques Dikansky
President and Chief Executive Officer

Tel.: +33 (0)4 90 23 96 89 naturex@naturex.com

Carole Alexandre

Investor Relations Tel.: +33 (0)4 90 23 78 28 c.alexandre@naturex.com **Thierry Lambert**

Vice-President Tel.: +33 (0)4 90 23 96 89 t.lambert@naturex.com

Anne Catherine Bonjour

Actus Finance Press Relations Tel.: +33 (0)1 53 67 36 93 acbonjour@actus.fr

